Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lymphoma 7Leukemia 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Renal Cell 5Unspecified Adult Solid Tumor, Protocol Specific 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Kidney Neoplasms 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Congenital Abnormalities 2Carcinoma, Ovarian Epithelial 2Blast Crisis 2Anemia, Refractory 2

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × bryostatin 1 × Clear all
NCT00005599 2013-06-21

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡